We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bringing One-day Genomic Profiling to Hematology Oncology
Product News

Bringing One-day Genomic Profiling to Hematology Oncology

Bringing One-day Genomic Profiling to Hematology Oncology
Product News

Bringing One-day Genomic Profiling to Hematology Oncology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bringing One-day Genomic Profiling to Hematology Oncology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a laborious and time-consuming workflow. In an effort to simplify and accelerate the genomic profiling process, Thermo Fisher Scientific has announced that the Ion Torrent Oncomine Myeloid Research Assay will be available in 2020 to run on the newly introduced Ion Torrent Genexus System, the first fully-integrated next-generation sequencing (NGS) platform featuring an automated workflow that can deliver results economically in a day with minimal user intervention and tissue sample input.

“For the past two years we have been using Thermo Fisher’s NGS technology to analyze myeloid samples, and the Oncomine Myeloid Research Assay provides a comprehensive assessment to identify relevant variants in a single step,” said Bekim Sadikovic, Ph.D., associate professor of pathology and laboratory medicine at Western University and division head of the Molecular Diagnostics Division in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre. “Making this assay available on a platform that can deliver results in a single day would provide labs with the answers they need for key mutations such as FLT3-ITDs, TP53, CEBPA, NPM1, KIT, PML-RARA and other biomarkers.”

Thermo Fisher introduced the Genexus System in November and will demonstrate the platform at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (booth #140) being held in Orlando, Fla. from December 7-10.

Expanded Portfolio Addresses Full Range of Hematology Applications

Thermo Fisher also announced an expanded portfolio of NGS-based hematology-oncology research assays that make it easier to assess lymphoid malignancies. The new Oncomine BCR IGH-LR Assay is designed to provide accurate clonality assessment and somatic hypermutation in chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The Oncomine BCR IGH-SR Assay aims to measure residual disease (MRD) in lymphoid malignancies with higher sensitivity and lower limit of detection (LOD) than traditional methods.

Thermo Fisher’s hematology portfolio includes the Oncomine Childhood Cancer Research Assay. All of Thermo Fisher’s hematology and oncology assays are compatible with the Ion GeneStudio S5 System, providing an end-to-end, streamlined NGS workflow for consolidated biomarker testing. The system also includes Thermo Fisher’s bioinformatics software in an effort to deliver more comprehensive information and easier interpretation of NGS biomarker testing.

Advertisement